Kinase modulators approved by FDA in 2022
10.16438/j.0513-4870.2023-0472
- VernacularTitle:2022年FDA批准的激酶调节剂浅析
- Author:
Xuan ZHENG
;
Xiao-yun LU
- Publication Type:Research Article
- Keywords:
iscovery background;
research and development process;
synthesis route;
clinical efficacy and safety
- From:
Acta Pharmaceutica Sinica
2024;59(1):61-75
- CountryChina
- Language:Chinese
-
Abstract:
The FDA approved a total of 37 new drugs in 2022, including 22 new molecular entities and 15 new biological products. This is the year with the lowest number of new drugs approved by the FDA since 2017. Among these approved drugs, 21 new drugs belong to the "first-in-class" category, accounting for 56% of the total approved drugs, which is the highest ratio in the past 10 years. Among the drugs approved in 2022, there are 5 small molecule kinase modulators, including the tyrosine kinase 2 (TYK2) allosteric inhibitor deucravacitinib, the first oral pyruvate kinase (PK) activator mitapivat, the Janus kinase 1 (JAK1) selective inhibitor abcrocitinib, the JAK2 selective inhibitor pacritinib and the broad-spectrum fibroblast growth factor receptor (FGFR) inhibitor futibatinib. This review briefly describes the discovery background, research and development process, synthesis routes and clinical efficacy and safety of small molecule kinase modulators approved by the FDA in 2022, hoping to provide ideas and methods for further research on kinase modulators.
